Literature DB >> 12946025

Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein.

Erwin Lauwers1, Zeger Debyser, Jo Van Dorpe, Bart De Strooper, Bart Nuttin, Veerle Baekelandt.   

Abstract

Two mutations in alpha-synuclein, the main constituent of Lewy bodies, have been identified in familial Parkinson's disease. We have stereotactically injected lentiviral vectors encoding wild-type and A30P mutant human alpha-synuclein in different brain regions (striatum, substantia nigra, amygdala) of mice. Overexpression of alpha-synuclein induced time-dependent neuropathological changes reminiscent of Lewy pathology: abnormal accumulation of alpha-synuclein in cell bodies and neurites, alpha-synuclein-positive neuritic varicosities and cytoplasmic inclusions that stained with ubiquitin antibodies and became larger and more frequent with time. After one year, alpha-synuclein- and ubiquitin-positive neurons displayed a degenerative morphology and a significant loss of alpha-synuclein-positive cells was observed. Similar findings were observed with both the wild-type and the A30P mutant form of alpha-synuclein and this in different brain regions. This indicates that overexpression of alpha-synuclein is sufficient to induce Lewy-like pathology and neurodegeneration and that this effect is not restricted to dopaminergic cells. Our data also demonstrate the use of lentiviral vectors to create animal models for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946025     DOI: 10.1111/j.1750-3639.2003.tb00035.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  32 in total

Review 1.  Parkinson's disease: a rethink of rodent models.

Authors:  Heather L Melrose; Sarah J Lincoln; Glenn M Tyndall; Matthew J Farrer
Journal:  Exp Brain Res       Date:  2006-04-26       Impact factor: 1.972

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Definition of a molecular pathway mediating α-synuclein neurotoxicity.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

4.  Alpha synuclein is transported into and out of the brain by the blood-brain barrier.

Authors:  Yu-Ting Sui; Kristin M Bullock; Michelle A Erickson; Jing Zhang; W A Banks
Journal:  Peptides       Date:  2014-09-30       Impact factor: 3.750

Review 5.  Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.

Authors:  Varduhi H Knaryan; Supriti Samantaray; Charlene Le Gal; Swapan K Ray; Naren L Banik
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

6.  Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.

Authors:  Simon Moussaud; Siobhan Malany; Alka Mehta; Stefan Vasile; Layton H Smith; Pamela J McLean
Journal:  Expert Opin Ther Targets       Date:  2015-03-18       Impact factor: 6.902

Review 7.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

8.  Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation.

Authors:  Angélique Deleersnijder; Anne-Sophie Van Rompuy; Linda Desender; Hans Pottel; Luc Buée; Zeger Debyser; Veerle Baekelandt; Melanie Gerard
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

9.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

10.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.